

Edgar Filing: BIOGENTECH CORP - Form DEF 14C

BIOGENTECH CORP  
Form DEF 14C  
June 10, 2004

SCHEDULE 14C INFORMATION STATEMENT  
Information Statement Pursuant to Section 14(c)  
of the Securities Exchange Act of 1934

Filed by the Registrant  Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Information Statement  
 Confidential, for Use of the Commission Only (as permitted  
by Rule 14a-6(e)(2))  
 Definitive Information Statement

BioGentech Corp.

-----  
Commission File Number: 000-49620

Payment of Filing Fee (Check the appropriate box):

- No fee required  
 Fee computed on table below per Exchange Act Rules 14c-5(g) and 0-11.

- 1) Title of each class of securities to which transaction applies: \_\_\_\_\_  
2) Aggregate number of securities to which transaction applies: \_\_\_\_\_  
3) Per unit price or other underlying value of transaction computed pursuant to  
Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is  
calculated and state how it was determined): \_\_\_\_\_  
4) Proposed maximum aggregate value of transaction: \_\_\_\_\_  
5) Total fee paid: \_\_\_\_\_

- Fee paid previously with preliminary materials.  
 Check box if any part of the fee is offset as provided by Exchange Act Rule  
0-11(a)(2) and identify the filing for which the offsetting fee was paid  
previously. Identify the previous filing by registration statement number, or  
the Form or Schedule and the date of its filing.

- 1) Amount Previously Paid: \_\_\_\_\_  
2) Form, Schedule or Registration Statement No.: \_\_\_\_\_  
3) Filing Party: \_\_\_\_\_  
4) Date Filed: \_\_\_\_\_

BioGentech Corp.  
2445 McCabe Way, Suite 150  
Irvine, California 92614

NOTICE OF ACTION TAKEN BY  
WRITTEN CONSENT OF MAJORITY  
SHAREHOLDERS

DEAR SHAREHOLDERS:

We are writing to advise you that BioGentech Corp. will change its name to  
Cobalis Corp. The name change was approved on May 27, 2004, by unanimous

Edgar Filing: BIOGENTECH CORP - Form DEF 14C

approval of our Board of Directors. In addition, shareholders holding a majority of our issued and outstanding common stock, approved the name change by written consent in lieu of a meeting on May 27, 2004, in accordance with the relevant sections of Nevada Revised Statutes. The name change will not be effective until we amend our Articles of Incorporation by filing a Certificate of Amendment to our Articles of Incorporation with the Nevada Secretary of State. We intend to file the Certificate of Amendment twenty days after this information statement is first mailed to our shareholders.

Our purpose in changing our name to Cobalis Corp. is to comply with the terms of an agreement that is the basis for a consent judgment against us in a case filed last year in the US District Court for the District of Massachusetts by Biogen Idec MA Inc., ("Biogen") alleging trademark infringement and unfair competition, under docket number CA No. 03-12305 PBS. In March 2004, we entered into an agreement with Biogen to settle the dispute wherein we will be enjoined from using the corporate names, trade names, trademarks or domain names containing "Biogentec" or "Biogentech" or any phonetic equivalent. We intend to continue development of our product under our new corporate name when the name change has been given effect.

No action is required by you. The accompanying information statement is furnished only to inform our shareholders of the action described above before it takes effect in accordance with Rule 14c-2 promulgated under the Securities Act of 1934. This information statement is being mailed to you on or about June 15, 2004.

WE ARE NOT ASKING YOU FOR A PROXY AND YOU ARE REQUESTED NOT TO SEND US A PROXY.

By order of the Board of Directors,

/s/ Chaslav Radovich

-----  
Chaslav Radovich  
PRESIDENT

Irvine, California  
June 9, 2004

BioGentech Corp.  
2445 McCabe Way, Suite 150  
Irvine, California 92614

INFORMATION STATEMENT REGARDING  
ACTION TAKEN BY WRITTEN CONSENT OF  
MAJORITY OF SHAREHOLDERS

We are furnishing this shareholder information statement to you to provide you with information and a description of an action taken by written consent of our majority shareholder, on May 27, 2004, in accordance with the relevant Sections of the Nevada Revised Statutes. This action was taken by shareholders who own in excess of the required majority of our outstanding common stock necessary for the adoption of the action.

WE ARE NOT ASKING YOU FOR A PROXY AND YOU ARE REQUESTED NOT TO SEND US A PROXY.

This information statement is being mailed on or about June 15, 2004 to

## Edgar Filing: BIOGENTECH CORP - Form DEF 14C

shareholders of record on May 27, 2004. The information statement is being delivered only to inform you of the corporate action described herein before it takes effect in accordance with Rule 14c-2 promulgated under the Securities Exchange Act of 1934.

### GENERAL

On May 27, 2004, our Board of Directors unanimously approved, subject to shareholder approval, an amendment to our Articles of Incorporation to change our corporate name to "Cobalis Corp." On May 27, 2004, shareholders who own in excess of the required majority of our outstanding common stock necessary for the adoption of the action, approved the name change by action taken by written consent. The full text of the proposed amendment to the Articles of Incorporation is attached hereto as Exhibit A.

### PURPOSE OF CHANGE IN NAME OF THE CORPORATION

Our purpose in changing our name to Cobalis Corp. is to comply with the terms of an agreement that is the basis for a consent judgment against us in a case filed last year in the US District Court for the District of Massachusetts by Biogen Idec MA Inc., ("Biogen") alleging trademark infringement and unfair competition, under docket number CA No. 03-12305 PBS. In March 2004, we entered into an agreement with Biogen to settle the dispute wherein we will be enjoined from using the corporate names, trade names, trademarks or domain names containing "Biogentec" or "Biogentech" or any phonetic equivalent. We intend to continue development of our product under our new corporate name when the name change has been given effect.

### PROCEDURE FOR APPROVAL OF NAME CHANGE; VOTE REQUIRED

The Nevada Revised Statutes requires that, in order for us to amend our Articles of Incorporation, such amendment must be approved by our Board of Directors and approved by a majority of the outstanding shares entitled to vote. The Nevada Revised Statutes also provides that any action which may be taken at a meeting of the shareholders may be taken without a meeting and without prior notice, if a consent in writing, setting forth the action so taken, shall be signed by the holders of a majority of the outstanding shares entitled to vote.

On May 27, 2004, the record date for determination of the shareholders entitled to receive this Information Statement, there were 23,792,666 shares of common stock outstanding. The holders of common stock are entitled to one vote for each share held of record on all matters submitted to a vote of our shareholders. We needed the affirmative vote of at least a majority of the outstanding shares of our common stock to approve the name change. Our Board, by its unanimous written consent, adopted resolutions approving an amendment to our Articles of Incorporation to effect the name change. By action of written consent, dated May 27, 2004, two shareholders who are affiliates and who own 11,370,000 shares of the issued and outstanding shares of our common stock, or 57.9% of the issued and outstanding shares of our common stock, approved the name change.

### EFFECTIVE DATE OF AMENDMENT

The amendment to our Articles of Incorporation will become effective upon the filing with the Nevada Secretary of State of the Certificate of Amendment to our Articles of Incorporation, attached hereto as Exhibit A. We intend to file the Certificate of Amendment twenty days after this Information Statement is first mailed to shareholders.

### EFFECT ON CERTIFICATES EVIDENCING SHARES OF BIOGENTECH CORP. STOCK

## Edgar Filing: BIOGENTECH CORP - Form DEF 14C

The change in the name of BioGentech Corp. will be reflected in its stock records by book-entry in BioGentech Corp.'s records. For those shareholders that hold physical certificates, please do not destroy or send to BioGentech Corp. your common stock certificates. Those certificates will remain valid for the number of shares shown thereon, and should be carefully preserved by you.

### DISSENTER'S RIGHTS

The Nevada Revised Statutes do not provide for dissenters' right of appraisal in connection with the name change.

### INTERESTS OF CERTAIN PERSONS IN MATTERS TO BE ACTED UPON

No director, executive officer, nominee for election as a director, associate of any director, executive officer or nominee or any other person has any substantial interest, direct or indirect, by security holdings or otherwise, in the proposed name change, which is not shared by all other shareholders of BioGentech Corp.

### SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth information regarding the beneficial ownership of the shares of our common stock as of May 27, 2004, except as noted in the footnotes below, by:

- o Each person who we know to be the beneficial owner of 5% or more of our outstanding common stock;
- o Each of our executive officers;
- o Each of our directors; and
- o All of our executive officers and directors as a group.

Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission. In computing the number of shares beneficially owned by a person and the percentage of ownership of that person, shares of common stock subject to options held by that person that are currently exercisable or become exercisable within 60 days of May 27, 2004, are deemed outstanding even if they have not actually been exercised. Those shares, however, are not deemed outstanding for the purpose of computing the percentage ownership of any other person. As of May 27, 2004, there were 23,792,666 shares of our common stock were issued and outstanding. Unless otherwise indicated in the table, the persons and entities named in the table have sole voting and sole investment power with respect to the shares set forth opposite the shareholder's name, subject to community property laws, where applicable. The address of each shareholder is listed in the table

| TITLE OF CLASS | NAME AND ADDRESS OF BENEFICIAL OWNER                                    | AMOUNT AND NATURE OF BENEFICIAL OWNER                             |
|----------------|---|---|
| Common Stock   | Chaslav Radovich (1)<br>2445 McCabe Way, Suite 150<br>Irvine, CA, 92614 | 306,200 shares<br>President, Secretary, Treasurer<br>and Director |
| Common Stock   | St. Petka Trust (2)<br>46 Calle Fresno<br>San Clemente, CA, 92672       | 12,369,441 shares   |

Edgar Filing: BIOGENTECH CORP - Form DEF 14C

|              |   |  |
|--------------|---|--|
| Common Stock | Radul Radovich (2)<br>46 Calle Fresno<br>San Clemente, CA, 92672                | 12,369,441 shares<br>Director  |
| Common Stock | Silver Mountain Promotions (2)<br>6446 Silver Dawn Lane<br>Las Vegas, NV, 89118 | 12,369,441 shares  |
| Common Stock | R&R Holdings (2)<br>46 Calle Fresno<br>San Clemente, CA, 92672                  | 12,369,441 shares  |
| Common Stock | James Luce<br>34 Van Gogh Way<br>Coto de Caza, CA, 92679                        | 12,500 shares<br>Chief Operating Officer, Chief<br>Marketing Officer |
| Common Stock | Ernest Armstrong (3)<br>2445 McCabe Way, Suite 150<br>Irvine, CA, 92614         | 2,120,000 shares<br>Vice President Business<br>Development           |
| Common Stock | Gene Pharmaceuticals (3)<br>2445 McCabe Way, Suite 150<br>Irvine, CA, 2614      | 2,020,000 shares   |
| Common Stock | Kevin Prendiville (4)<br>1791 Franquers Ln<br>Cottonwood, AZ, 86326             | 397,500 shares<br>Director   |
| Common Stock | Officers and directors as a group   | 15,179,366 shares  |

(1)Chaslav Radovich owns 262,200 individually and is the custodian of the 44,000 shares owned by Milena Radovich, his minor child.

(2)Radul Radovich is one of the beneficiaries of the St. Petka Trust, which owns 11,750,000 shares. Radul Radovich and his spouse are the owners of R&R Holdings which holds 20,333 shares of our common stock, and of Silver Mountain Promotions, which holds 572,833 shares of our common stock.

(3)Ernest Armstrong owns 100,000 individually and is the sole owner of Gene Pharmaceuticals, LLC, which owns 2,020,000 shares.

(4)Kevin Prendiville owns 12,500 shares directly and is one of the trustees of the Prendiville Revocable Trust, owner of 385,000 shares.

Exhibit A

Certificate of Amendment  
(Pursuant to NRS 78.385 and 78.390)

Certificate of Amendment to Articles of Incorporation  
For Nevada Profit corporations  
(Pursuant to NRS 78.385 and 78.390 - After Issuance of Stock)

1. Name of corporation: Biogentech Corp.

2. The articles have been amended as follows (provide article numbers, if available):

Edgar Filing: BIOGENTECH CORP - Form DEF 14C

I. The name of this corporation is to Cobalis Corp.

3. The vote by which the stockholders holding such shares in the corporation entitling them to exercise at least a majority of the voting power, or such greater proportion of the voting power as may be required in the case of a vote by classes or series, or as may be required by the provisions of the \* articles of incorporation have voted in favor of the amendment is:  
-----

4. Effective date of filing (optional): \_\_\_\_\_  
(must not be later than 90 days after the certificate is filed)

5. Officer Signature (required): \_\_\_\_\_

\*If any proposed amendment would alter or change any preference or any relative or other right given to any class or series of outstanding shares, then the amendment must be approved by the vote, in addition to the affirmative vote otherwise required, of the holders of shares representing a majority of the voting power of each class or series affected by the amendment regardless of limitations or restrictions on the voting power thereof.

IMPORTANT: Failure to include any of the above information and submit the proper fees may cause this filing to be rejected.